- Recipharm has announced a multi-million-dollar investment in its US operations to expand sterile fill and finish manufacturing capacity for biologics and advanced therapies.
- The investment follows a clinical biologics fill and finish agreement with a major global pharmaceutical company and includes expanded capabilities across development, scale-up, clinical and commercial manufacturing.
Recipharm has announced a multi-million-dollar investment in its US operations to expand sterile fill and finish manufacturing capacity for biologics and advanced therapies. The CDMO said the investment is intended to strengthen support for pharmaceutical and biotechnology companies by providing expanded access to clinical and commercial manufacturing services in the United States.
The company said the investment will enhance its manufacturing infrastructure and technical capabilities, supporting customers across the product lifecycle from development and scale-up through clinical and commercial supply. According to Recipharm, the expansion is designed to increase manufacturing capacity, accelerate development timelines, and improve access to US-based manufacturing services.
The announcement follows the signing of a clinical biologics fill and finish agreement with a major global pharmaceutical company. Recipharm said the agreement reflects demand for manufacturing solutions and domestic capacity for biologics and advanced therapies.
“The demand for biologics and advanced therapies continues to accelerate, and manufacturers must be ready to meet that challenge with the right capacity, expertise and technology. By expanding our sterile manufacturing capabilities, we are investing in the infrastructure needed to support the next wave of pharmaceutical innovation.”
Greg Behar, CEO of Recipharm
Recipharm also said it has enhanced its aseptic manufacturing platform to support clinical and commercial programs in North America and Europe. The company is expanding its sterile manufacturing and contract manufacturing offering to include API compounding, analytical transfer and validation, process characterisation, process performance qualification (PPQ), and aseptic fill and finish manufacturing. The expanded offering complements its existing US capabilities in nucleic acids, RNA, lipid nanoparticle development and manufacturing, analytical services, bacterial cell banking, and sterile fill and finish operations.
